EP Patent

EP2470657B1 — Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap

Assigned to Curna Inc · Expires 2019-10-23 · 7y expired

What this patent protects

Patent listed against inclisiran-sodium.

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: EP2470657B1
Jurisdiction: EP
Classification: —
Expires: 2019-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Curna Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.